RT Journal Article
SR Electronic
T1 Development of a list with renally relevant drugs as a tool to increase medicines optimisation in patients with chronic kidney disease
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP 46
OP 52
DO 10.1136/ejhpharm-2020-002571
VO 30
IS 1
A1 Schütze, Alexander
A1 Benöhr, Peter
A1 Haubitz, Marion
A1 Radziwill, Roland
A1 Hohmann, Carina
YR 2023
UL http://ejhp.bmj.com/content/30/1/46.abstract
AB Objectives Chronic kidney disease (CKD) is a common disorder all over the world. Therapeutic goals are early detection of declining renal function and implementation of adequate pharmacological treatments regarding underlying and secondary diseases. As therapy becomes more complex with increasing stages of CKD, a decision-making tool for healthcare professionals could help to ensure safe drug treatment in patients with CKD in the outpatient setting. Therefore, a list of renally relevant drugs as a decision-making tool was developed to improve medicines optimisation for CKD patients in the outpatient setting long term.Methods A renally relevant drug list (RRD-list) with renally relevant drugs, based on data from a study on medicines optimisation in patients with CKD from June 2015 to March 2018, was developed at the nephrological outpatient clinic at the Klinikum Fulda, Germany. The whole study is published elsewhere. A clinical pharmacist reviewed the patients’ medications, current drug-related problems and all nephrologists’ recommendations, and categorised all detected drugs into renally relevant and non-renally relevant groups. The 10 most frequently detected renally relevant drug groups were summarised in the RRD-list and extended by treatment alternatives and advice.Results The medication of 160 patients, who were receiving overall 1376 drugs, was analysed; 831 drugs were defined as renally relevant. Drug-related problems were caused by 543 renally relevant drugs. The nephrologists made 292 recommendations regarding 28 drug classes. Considering the 10 most frequent drug groups, in total 16 renally relevant drug groups with 36 drug classes were added to the RRD-list.Conclusions The RRD-list could be an essential tool for all healthcare professionals in their daily work, such as general practitioners and community pharmacists, for the treatment of patients with renal insufficiency.The data are de-identified participant data. Data are available upon reasonable request from the corresponding author. Re-use is not permitted.